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2Abstract
Background
Delays in diagnosis and treatment for malaria are associated with an increased risk for severe
disease and mortality. Identifying the extent of patient and health system delay can provide a
benchmark against which interventions to reduce delays can be measured.
Methods
We performed an electronic search in PubMed, EMBASE, Web of Science and LILACS for studies
reporting time to diagnosis and treatment after return from travel, onset of symptoms and seeking
healthcare in non-endemic countries. Additionally, theses, conference proceedings and nationally
reported surveillance data were also searched for information on time delays. There were no
language restrictions and all the studies were assessed for methodological quality.
Results
Data from 69 papers out of 1,719 identified records published between 2005 and 2017 were
extracted; our findings show that median diagnosis delays of four or more days are common and
patient delays accounted for a large proportion of diagnostic delay. There were limited data
available on medical diagnostic delay.
Conclusion
Patient delays accounted for a large proportion of the overall diagnostic delay; however the
retrospective nature of the studies could have overestimated patient delay since previous
healthcare contacts were not included. Additionally, the high frequency of studies reporting a
clinically significant delay is a major concern.
3Background
Prompt diagnosis and treatment of malaria remains a challenge in non-endemic countries [1]. Both
patient factors and medical factors can lead to delays in diagnosis and treatment. In non-endemic
countries specifically, differing immunogenic profiles, chemoprophylaxis use, the small number of
cases and the non-specific symptoms associated with malaria add to the challenge of early diagnosis
and treatment [1], [2], [3]. Furthermore, it is likely to become more challenging as the number of
imported malaria cases decline due to global malaria eradication efforts [4].
Identifying where the greatest delays occur can provide a benchmark against which interventions to
reduce delays can be measured. In this review, we describe the duration of delay at different time
periods leading up to a diagnosis and treatment of malaria in non-endemic countries. Additionally,
we describe the delays by parasite species given the species specific variations in disease
manifestation, and the heterogeneity in the composition of plasmodium species types imported to
non-endemic countries [5]. Finally, we discuss the implications of how data on delay are collected
and reported amongst the included studies on the interpretation of the results of this review.
Methods
Search strategy
The search was carried out in three stages. The first stage involved searching for published academic
papers in electronic databases (PubMed, Web of Science, EMBASE and LILACS). The second stage
involved searching for unpublished work in grey literature databases. The final stage involved
searching for nationally reported malaria surveillance data from non-endemic countries. The search
was restricted to studies published from January 2005 to November 2016 to retrieve contemporary
data and there were no language restrictions. A detailed search strategy including the search terms
used for each stage is summarised in appendix A.1. The systematic review protocol has been
registered and published on PROSPERO (Record number: CRD42016045259).
4Inclusion criteria
Observational studies including case series, case control and cohort studies which reported on time
delays were included. For case control studies specifically, studies were only included if all malaria
patients at the study centre were recruited as cases, and if the time delays were reported at
baseline. This was done to minimise the effect that selection bias might have on the results of the
review.
Studies with participants of all ages diagnosed with malaria in a non-endemic country were included
in the review irrespective of whether they focused on a specific ethnicity or traveller group (e.g.
those who visit friends and relatives overseas). Studies were grouped by parasite species (i.e. P.
falciparum, P. vivax, P. ovale, and P. malariae) provided that the majority (greater than 70%) of the
participants in the study were attributable to that species. Studies that did not report the parasite
species or had less than 70% of cases attributable to a specific parasite species were included in the
“mixed” category. Additionally, studies which reported data for severe malaria or children (aged
<=18 years) were included and analysed separately. The severe malaria category consisted of studies
which reported cases of severe malaria as per the WHO classification, or those who have been
admitted to ICU with malaria, or fatal cases of malaria [6].
Studies were included in the review if they recruited >=20 participants, were conducted in a non-
endemic country according to the WHO official register and supplementary list (2012) (Appendix
A.1) [7], had a study period which ended after the 1st of January 2000 and report on any of the
following outcomes (Figure 1):
 Time to onset of symptoms (TOS): This is defined as the time between returning from a
malaria endemic country and the onset of symptoms for malaria.
 Diagnostic delay (DD): For this review, diagnostic delay is defined as the time between the
onset of symptoms and the diagnosis of malaria.
5 Delay in seeking healthcare: This is also known as patient delay (PD) and is defined as the
time between the onset of symptoms and first attending a medical facility or seeking
healthcare advice.
 Medical diagnostic delay (MDD): This is defined as the time between first attending a
medical facility or seeking healthcare advice and the diagnosis of malaria.
 Treatment delay (TD): This is defined as the time between the onset of symptoms and the
initiation of treatment for malaria.
 Medical treatment delay (MTD): This is defined as the time between first attending a
medical facility or seeking healthcare advice and the initiation of treatment for malaria.
Figure 1. A timeline summarising the definitions of the various time delays included in this review
When more than one study described data from the same source, the study with the more complete
data was selected for the review. If the completeness of the data was similar, then the more recent
data were selected for the review.
6Data collection
The citations of the studies retrieved using the review’s search strategy were downloaded, indexed
and de-duplicated using Endnote version x7. The title and abstracts were screened independently by
two reviewers (HB and JC) to identify studies which potentially met the inclusion criteria. The full
text of all potentially relevant articles was obtained and reviewed and the reviewers (HB and JC)
independently classified the studies into the following categories: “include”, “exclude” or “unclear”.
Disagreements in the classification of the studies were resolved by consensus or by a third reviewer
(GR) if no agreement was reached. A similar approach was used for the studies which were classified
as “unclear” to reach a decision on whether to include or exclude the study. The reason for exclusion
for all the rejected studies was documented and is summarised in the results (Figure 2).
Data extraction
Data were extracted from the studies selected for inclusion using a standardised data collection
form. The data extracted included: study author, study year, study design, country, description of
study participants, sample size, proportion of participants with P. falciparum infection and the main
outcomes (time to the onset of symptoms, diagnostic delay, patient delay, medical diagnostic delay,
treatment delay and medical treatment delay). For the main outcomes, data were extracted if either
the mean or the median duration of delay was reported, as well as the standard deviation (SD) or
interquartile range (IQR).
Both reviewers independently extracted the data and entered it into an Excel spreadsheet. The
extracted data in both Excel spreadsheets were checked by HB for inconsistencies and both
reviewers (HB and JC) re-reviewed the studies if any were found to ensure the correct data were
extracted. If the studies selected for inclusion had relevant unreported data, the study’s
corresponding author was contacted by email to request the data.
7All studies which were included in the review were assessed for methodological quality using the
“JBI critical appraisal checklist” (appendix A.2).
Data Synthesis
Extracted data from the studies were summarised in tables to provide a descriptive synthesis of the
included studies. The tables were presented separately for each of the time delays (TOS, DD, PD,
MDD, TD and MTD). The data in each of the tables were categorised in subgroups according to the
plasmodium species (P. falciparum, P. vivax, P. ovale, P. malariae and mixed species). Studies which
specifically reported on children and those with severe malaria were categorised separately within
the tables.
For studies which report both the median and the IQR (25th and 75th percentile), the data were
summarised in boxplots to allow for comparison of the delays between the included studies.
Additionally, for studies which reported median delays, a summary median, IQR and range was
provided using boxplots for P. falciparum and P. vivax only.
Results
Description of studies
Electronic database search
The PubMed search retrieved a total of 1,061 citations. Excluding studies already retrieved from the
PubMed search, the WOS, EMBASE and LILACS searches retrieved a further 169, 109 and 32 citations
respectively. In total the electronic databases searches retrieved 1,371 citations of which 64 studies
met the inclusion criteria.
8Grey Literature search
The grey literature search retrieved a total of 253 citations. Of these, 18 were considered for full text
review after reviewing the title and abstracts of the theses and conference proceedings. A further 7
were excluded after reviewing the full text. The full text was not available for 11 theses (non-
loanable) either online or through interlibrary loans. Therefore there were no studies added to the
review as a result of the grey literature search.
National agency reports
Of the 94 countries certified as non-endemic by the WHO, the organization responsible for the
surveillance of imported malaria was identified in 85 of them. Publicly available reports on malaria
surveillance were identified from 64 of these organisations, however, for the majority of these (N=
60), the reports contained annual summaries on the number of imported malaria cases with no
information on time delays. For 3 organisations (France, Tunisia and Le Reunion), information on
time delays was available and data from the surveillance summaries reported by these organisations
were included in the review. For France, annual surveillance data is published in the “Centre
National de Référence sur le Paludisme” (CNRP) website and data on time delays is available for the
years 2006 to 2010 [8]. For Tunisia and Le Reunion, information on time delays was available for the
years of 2002-2007 and 2003- 2007 respectively. For a further 2 organisations, the Centres for
Disease Control and Prevention (United States) and National Institute of Public Health (Poland),
annual surveillance summaries reported data on time delays, however no mean or median was
reported. The authors of the surveillance reports were contacted and data from these 2
organisations were included in the review [9], [10].
Included studies
There were a total of 69 studies included in the review following the electronic database, grey
literature and national agency report searches (Figure 2). In some of these studies, data were
9available for a number of species of malaria as well as different time delays resulting in the same
study contributing data for a number of different outcomes in this review. A table summarizing the
characteristics of the included studies as well as the delays reported in the studies can be seen in
(appendix A.5). There were no studies excluded after quality assessment (appendix A.2).
In terms of study setting, most were conducted in France (n = 17) followed by Spain (n = 8), the UK
(n = 6) and the US (n = 4) (appendix A.3). Studies from the USA and France, which reported national
Figure 2. Flowchart of included studies
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surveillance data, had the largest number of participants. In terms of parasite species, studies which
report data for P. falciparum and P. vivax had a larger number of participants compared to P. ovale
and P. malariae.
The number of studies contributing data to each of the time points included in this review, and the
range of reported median and mean duration for those time points by parasite species is
summarised in (appendix A.4). Additionally, data were available for 96 patient groups from 28
studies that had reported both a median and IQR for TOS, DD and PD. There were limited data
available for MDD, MTD and TD.
Time to the onset of symptoms after return from travel
The TOS for studies that reported both a median and an IQR is summarised in a box plot (Figure 3).
This shows that, the median time to onset of symptoms is longer in those who had contracted non
falciparum malaria compared to those who had contracted falciparum malaria. Additionally, the
wider IQR amongst the non-falciparum patient groups indicates greater variability on when
symptoms can first appear after return from travel, compared to the falciparum patient groups.
Amongst the non-falciparum studies, the majority of the patient groups with P. malariae had a
shorter reported median for the TOS compared to P. vivax and P. ovale. For P. ovale specifically, the
smallest and largest medians were reported in 2 patient groups within the same study [11]. In this
study, the TOS was reported separately for the 2 subspecies of P. ovale; P. ovale curtisi (a) and P.
ovale wallikeri (b), whereas the other included studies for P. ovale reported the data for both
subspecies together.
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Diagnostic Delay
The DD for studies that reported both a median and an IQR is summarised in (Figure 4). This shows
that, amongst these studies, there is no considerable difference in the median DD between the
different parasite species (range 3 to 9 days), except for the study by Alaya-Bouafif et al. which
reported a larger median delay. In this study, DD was compared between Tunisians (14 days) and
non-Tunisians (12.5 days) regardless of Plasmodium species [12].
Figure 3. A summary of the TOS in studies which have reported both the median and the IQR. The central line represents the median
and the box represents the IQR.
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Patient Delay
The PD for studies that reported both a median and an IQR is summarised in (Figure 5). In these
studies, the median PD is comparable for most parasite species (2 to 6 days) except for P. malariae
where the medians for the PD are comparatively larger (7 to 9 days).
Figure 4. A summary of DD in studies which have reported both the median and the IQR. The central line represents the median and
the box represents the IQR.
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For both P. falciparum and P. vivax, the median PD and DD were similar in the studies which
reported a median and were included in the review (Figure 6). For P. falciparum, the overall median
DD was 3.25 days and median PD was 3 days. For P. vivax, the overall median DD was 3.75 days and
median PD was 4 days.
Figure 5. A summary of PD in studies which have reported both the median and the IQR. The central line represents the median and the
box represents the IQR.
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Medical diagnostic delay
There was limited data available amongst the included studies on MDD. A total of 5 studies reported
MDD for 7 different patient groups. Data were available for P. falciparum (n = 1), severe P.
falciparum (n = 1), P. falciparum in children (n = 2), P. vivax (n = 1) and mixed species (n =2)
(appendix A.4).
The median reported MDD for all P. falciparum groups was 0 days with 3 studies reporting a mean
MDD of between 0.7 and 1.5 days. For P. vivax and mixed species, the reported median MDD ranged
from 4 to 7.5 days, and the mean MDD from 4.6 to 8.8 days.
Treatment delay
Only 2 included studies reported data on treatment delay (appendix A.5).
Figure 6. A box and whisker plot summarising the median reported PD and DD for P. falciparum and P. vivax amongst the studies that
had reported a median. The boxplots show the median (central line), IQR (boxes) and range (whiskers) of the reported medians
15
One study reported a mean TD of 4 days for those who had uncomplicated P. falciparum [13]. The
second study reported a median TD of 1.5 days for patients with severe malaria that was fatal and
4.5 days for those that recovered [14].
Medical treatment delay
Similar to MDD, there was limited data available amongst the included studies for MTD. A total of 5
studies reported MTD for 6 different patient groups. Data were available for P. falciparum (n = 2),
severe P. falciparum (n = 1), P. falciparum in children (n = 1), P. vivax (n = 1) and mixed species in
children (n =1) (appendix A.5).
All studies reported a median MTD of less than 1 day for all patient groups except for the study by
Maltezou et al, which reported a median MTD of 2 days for children with malaria (mixed) [15].
Discussion
Our systematic review showed that there are considerable time delays in the diagnosis of malaria in
non-endemic countries. Delays in seeking healthcare by patients accounted for a large proportion of
the overall diagnostic delay; however there was limited evidence on delays to diagnosis and
treatment after attending a healthcare facility. Furthermore, the review also showed that symptoms
can manifest up to a year after return from travel.
Although there is no clear consensus of what is considered an acceptable duration for diagnostic
delay, a study by Seringe et al. showed that a DD of between 4 and 12 days is associated with an
increased risk of developing severe disease for P. falciparum [16]. In the absence of a defined lower
limit for DD and given that even those with prompt health seeking after symptom onset, and early
diagnosis after presentation, will have some degree of delay, we used a working definition for DD to
be greater than 4 days. In our review, 5 out of 14 studies reported a median DD of 4 days or greater
for P. falciparum, suggesting that improvements in diagnosis could potentially reduce the number of
people who develop severe disease in these centres [17], [18], [19], [20], [21]. Interestingly, in the 4
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studies which specifically looked at patients with severe P. falciparum only, the reported median DD
was greater than 4 days in all of them (median DD ranged from 5 to 7 days) [22], [23], [24], [25].
In relation to where the greatest delays occur, our findings suggest that patient factors result in the
greatest delays in diagnosis since the median duration for PD and DD were similar. However, the lack
of information on other delays (medical diagnostic delay, treatment delay and medical treatment
delay) and the retrospective nature of the studies included in this review could have resulted in an
overestimation for the true value for PD. This is because information regarding previous healthcare
visits, either to other hospitals or to a primary care physician, might not have been considered as
patient delay was estimated from symptom onset to attending the facility where the data were
collected in some studies [26]. Furthermore, the overestimation of PD would thus result in an
underestimation for data related to MDD since the previous healthcare visits which were not
considered would shorten the duration for PD and prolong it for MDD. This degree of
underestimation could be considerable, since several studies that have specifically looked at
previous visits to primary care and other non-specialist centres have reported a large proportion of
misdiagnosis of 61% and 80% in these settings. Moreover, a study by Dorsey et al which had looked
at malaria misdiagnosis showed that a missed diagnosis resulted in a mean delay in therapy of 5.6
days [26], [27], [28].
Although not an actual delay, given the individual is asymptomatic during this period and would
have no reason to seek healthcare, the time to onset of symptoms after return to travel was
included in the review since increased understanding on when malaria symptoms develop after
return from travel can increase awareness for those working in primary care on when to consider a
diagnosis of malaria. Our results corroborate current recommendations to consider a diagnosis of
malaria up to a year after returning from a malaria endemic country since the largest value for the
75th percentile of TOS in any of the included studies was 297 days [11], [29].
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Other findings of the review reflect existing evidence on the variations in clinical presentation due to
the different parasite species. These include; a longer duration until onset of symptoms for P. vivax
and P. ovale since their lifecycle consists of dormant liver stage parasites (hypnozoites), and, a
prolonged duration for seeking healthcare in those with P. malariae compared to other species,
possibly due to the milder form of illness making those affected less likely to seek healthcare earlier
[30], [31], [32].
It was difficult to make cross country comparisons given the variation in population characteristics,
traveller profiles and service delivery within the same country. For example, Fernandez-Lopez (2015)
reported a median diagnostic delay of 4 days (IQR: 2.5 -7) in 185 cases diagnosed in Fuenlabrada,
Spain, whereas, Millet (2008) reported a median diagnostic delay of 8 days (IQR: 5 - 20) in Barcelona,
Spain [19], [21]. This difference could be attributable to the increased clinical suspicion for malaria
due to the high incidence of malaria seen at the hospital in Fuenlabrada, an area with a large
immigrant population from endemic areas (99.4% of cases VFR or recently arrived immigrants in
Fuenlabrada vs. 54.3% in Barcelona). This hospital had also adopted universal testing of all attendees
who are originally from Sub-Saharan Africa resulting in an earlier diagnosis compared to Barcelona
[21].
The assembly of data from different publicly available sources resulted in a large number of included
studies, allowing comparison of delays by parasite species. However the variations in the
characteristics of the reported data and the reporting of medians due to the skewed nature of the
data on delays meant that a meta-analysis could not be done and thus the sample size of each study
is not reflected in the results (Figures 3, 4 and 5). Therefore when interpreting data from the graphs
in the results it is important to take into account the sample sizes which are reported in (Appendix
A.5).
Since diagnostic delays are still common in non-endemic countries; strategies to reduce both the
patient and healthcare factors should be promoted. This can include encouraging travellers to seek
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pre-travel health advice; which can inform them on recognising malaria symptoms and to seek
healthcare promptly [33]. Additionally, reminding travellers and healthcare providers that malaria
symptoms can develop up to 1 year after return from travel could make the travellers more likely to
disclose their travel history and healthcare providers more likely to consider a diagnosis of malaria if
symptoms arise within that period. Other strategies that identify cases in the absence of clinical
suspicion should be considered as well. For example, modern haematology analysers have been
used to detect malaria from tests done routinely in the work-up of a febrile patient. This could
prompt further malaria specific investigations in otherwise unsuspected cases and thus reducing DD
in these individuals [34].
Finally, the findings of this review also suggest that further evaluation of MDD is needed since the
retrospective nature of the studies included in this review may have resulted in its underestimation.
One method of evaluating this prospectively is to use routinely collected data from electronic health
records to investigate the provision of healthcare in primary care prior to when a diagnosis is made.
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2A.1. Search strategy
Electronic database search
The databases used for the electronic database search were: PubMed, Web of Science, EMBASE and
LILACS.
The search terms used to identify relevant articles were developed based on a modified version of
the PICO (Participant/ Intervention/ Comparison/ Outcome) search strategy. 1 The “Comparison”
component of this search strategy was not relevant given the descriptive nature of the review;
however, since the review focuses on the diagnosis and treatment of malaria in the non-endemic
setting, a component with search terms related to this setting were added instead. The full search
strategy used for the electronic database search is summarised in the table below:
The following search terms were used for the PubMed, Web of Science and EMBASE searches:
Population:
Patients diagnosed with
malaria
Malaria OR falciparum OR vivax OR plasmodium
AND
Intervention:
Diagnosis or treatment
diagnosis OR diagnostic OR evaluation OR therapy OR treatment OR care OR
symptom*
AND
Setting:
Non-endemic
imported OR travel* OR non-endemic OR return*
AND
Outcome:
Delay
delay* OR missed OR day OR days OR duration OR time* OR onset OR age
Additional limits:
 Studies published after 1st of January 2005
 Both the Web of science and EMBASE searches excluded studies which were indexed in
Medline
3For LILACS, the reduced number of articles indexed in it compared to the other electronic databases
meant that searching for all the four components described above yielded no results. Therefore, to
broaden the search, the terms “imported” and “malaria” was used for the LILACS database search.
Grey literature database search
To identify conference proceedings, theses and other unpublished articles and reports with
potentially relevant data, the following grey literature databases were searched:
 For conference proceedings, the Web of Science core collection database was searched and
the search was restricted to identify conference proceedings only.
 For theses, the DART-Europe E-theses portal, the e-theses online service by the British
Library (EThOS) and the System for information on Grey Literature in Europe (Open Grey)
databases were searched.
 To identify other unpublished health related articles and reports, the Grey Literature Report
archives (GreyLit) was searched.
The reduced number of articles indexed in the grey literature databases compared to the electronic
databases meant that searching for all the 4 components described previously yielded no results.
Therefore, to broaden the search, the terms “imported” and “malaria” was used for the grey
literature databases.
National agency reports
Malaria is a notifiable disease in a number of non-endemic countries and statistics related to
imported malaria within those countries is usually summarised into annual reports. The agencies
responsible for reporting data on malaria differ in each of the non-endemic countries and can
include national laboratories, ministries of health, institutes of public health and various other
governmental agencies. To search for publicly available reports, firstly, the agency responsible for
compiling and reporting malaria statistics in each non-endemic country was identified. Secondly,
once identified, their website was searched to obtain any publicly available datasets, reports or
summary statistics on malaria cases. Finally, once the summary statistics for the imported malaria
cases was obtained, the data reported were reviewed and were included if information on time
delays in the diagnosis and treatment of malaria were available. A summary of the reporting agency
for each of the non-endemic countries as well as the type of data available is summarised below.
4Summary of malaria reporting agency for each malaria non-endemic country
Table 1 Countries certified as malaria free by the WHO in 2012 and the reporting agency where information on time
delays were searched. An (x) indicates that the country was added to the WHO supplementary list in 2012.
Country Year
Certified as
malaria Free
by WHO
Type of data reported Reporting agency
Lesotho x Unable to access MOH website Ministry of Health
Mauritius 1973 Surveillance reports incidence. No time delays. Ministry of Health and Quality
of Life
Seychelles x Surveillance reports incidence. No time delays. Ministry of Health
Bahrain x Surveillance reports incidence. No time delays. Ministry of Health
Jordan x Surveillance reports incidence. No time delays. Ministry of Health
Kuwait 1963 Surveillance reports incidence. No time delays. Ministry of Health
Lebanon x Surveillance reports incidence. No time delays. Ministry of Health
Libya x Surveillance reports incidence. No time delays. Ministry of Health
Morocco 2010 Surveillance reports incidence. No time delays. Ministry of Health
Qatar x Surveillance reports incidence. No time delays. Ministry of Public Health
Tunisia x Data on time delays available ( Alaya-Bouafif
2011)
National Observatory of New
and Emerging Diseases of
Tunisia
United Arab
Emirates
2007 Surveillance reports incidence. No time delays. Ministry of Health
Andorra x No surveillance data on malaria Department of Health
Armenia 2011 Unable to access MOH website Ministry of Healthcare
Austria 1963 Surveillance reports incidence. No time delays. Federal Ministry of Health and
Women’s Affairs
Belarus x Surveillance reports incidence. No time delays. Public Health Services and
Medical Science in Belarus
Belgium 1963 Reflab responsible for surveillance. No data
available.
National reference laboratory
for infectious and tropical
diseases
Bosnia and
Herzegovina
1973 No info on surveillance Federal Ministry of Health
5Bulgaria 1965 NATIONAL REFERENCE LABORATORY (NRL) for
Diagnosis of Parasitic Diseases. Data not
available on site.
Ministry of Health
Croatia 1973 Surveillance reports incidence. No time delays. Croatian Institute of Public
Health
Cyprus 1967 No data on imported malaria cases Ministry of Health
Czech
Republic
1963 Surveillance reports incidence. No time delays. Ministry of Health
Denmark 1963 Surveillance reports incidence. No time delays. Statens Serum Institut
Estonia x Surveillance reports incidence. No time delays. National Institute for Health
Development
Finland 1963 Surveillance reports incidence. No time delays. National Infectious Diseases
Register (NIDR)
France (with
exception of
French
Guiana and
the island
Mayotte)
x Data on time delays available Centre Nationaux de reference
de paludisme
Germany 1964 Surveillance reports incidence. No time delays. Robert Koch Institute
Greece x Surveillance reports incidence. No time delays. Hellenic Center for Disease
Control & Prevention
Hungary 1964 Surveillance reports incidence. No time delays. National Center for
Epidemiology
Iceland 1963 Surveillance reports incidence. No time delays. Directorate of Health
Ireland 1963 Surveillance reports incidence. No time delays. Health Protection Surveillance
Centre
Israel x Surveillance reports incidence. No time delays. Ministry of Health
Italy 1970 Surveillance reports incidence. No time delays. L’Istituto Superiore di Sanità
Kazakhstan x No info on surveillance Ministry of Health
Latvia x Surveillance reports incidence. No time delays. Ministry of Health
Lithuania x No data on imported malaria cases Ministry of Health
Luxembourg x No info on surveillance Ministry of Health
Malta 1963 Surveillance reports incidence. No time delays. Ministry of Health
Monaco 1963 No info on surveillance Ministry of Health and Social
Affairs
Montenegro 1973 Surveillance reports incidence. No time delays. Centre for Disease Control and
Prevention
Netherlands 1970 Surveillance reports incidence. No time delays. National Institute for Public
Health and the Environment
Norway 1963 Surveillance reports incidence. No time delays. Norwegian Surveillance System
for Communicable Diseases
(MSIS)
6Poland 1967 Author contacted - Data on time delays
available
National Institute for Public
Health
Portugal 1973 No access to surveillance data National Health Service
Republic of
Moldova
x Surveillance reports incidence. No time delays. Ministry of Health
La Réunion,
France
1979 Data on time delays available Agence de Sante ocean Indien
Romania 1967 No data on imported malaria cases National Centre for Public
Health Information and
Statistics
Russian
Federation
x No data on time delays Federal Service for service of
consumer protection and
welfare
San Marino 1963 No info on surveillance Ministry of Health
Serbia 1973 Surveillance reports incidence. No time delays. Institute of Public Health of
Serbia
Slovakia 1963 No data on imported malaria cases Epidemiological Information
System
Slovenia 1973 Surveillance reports incidence. No time delays. Institute of Public Health of
Republic of Slovenia
Spain 1964 Surveillance reports incidence. No time delays. Instituto de salud carlos III
Sweden 1963 Surveillance reports incidence. No time delays. National Institute of Public
Health
Switzerland 1963 Surveillance reports incidence. No time delays. Federal Office for Public Health
The former
Yugoslav
Republic of
Macedonia
1973 Surveillance reports incidence. No time delays. Republic Institute for Health
Protection
Turkmenistan 2010 No info on surveillance Ministry of Health
Ukraine x Surveillance reports incidence. No time delays. Ministry of Health
United
Kingdom
1963 Surveillance reports incidence. No time delays. PHE / Malaria Reference
Laboratory
Antigua and
Barbuda
x Surveillance reports incidence. No time delays. Caribbean Public Health Agency
Bahamas x Surveillance reports incidence. No time delays. Caribbean Public Health Agency
Barbados 1968 Surveillance reports incidence. No time delays. Caribbean Public Health Agency
Canada 1965 Surveillance reports incidence. No time delays. Public Health Agency of Canada
Chile 1968 Surveillance reports incidence. No time delays. Department of Statistics and
Health Information
Cuba 1973 Surveillance reports incidence. No time delays. Institute of Tropical Medicine
'Pedro Kouri'
Dominica 1966 Surveillance reports incidence. No time delays. Caribbean Public Health Agency
Grenada 1962 Surveillance reports incidence. No time delays. Caribbean Public Health Agency
Jamaica 1966 Surveillance reports incidence. No time delays. Caribbean Public Health Agency
7Saint Kitts and
Nevis
x Surveillance reports incidence. No time delays. Caribbean Public Health Agency
Saint Lucia 1962 Surveillance reports incidence. No time delays. Caribbean Public Health Agency
Saint Vincent
and the
Grenadines
x Surveillance reports incidence. No time delays. Caribbean Public Health Agency
Trinidad and
Tobago
1965 Surveillance reports incidence. No time delays. Caribbean Public Health Agency
United States
of America
1970 Author contacted - Data on time delays
available
National Malaria Surveillance
System through CDC
Uruguay x Surveillance reports incidence. No time delays. Ministry of Health
Venezuela
(Bolivarian
Republic of,
northern
part)
1961 Surveillance reports incidence. No time delays. Ministry of Public Health
Maldives x No data on imported malaria cases Ministry of Health
Australia 1981 Surveillance reports incidence. No time delays. National Notifiable Diseases
Surveillance System
Brunei
Darussalam
1987 No data on imported malaria cases Ministry of Health
China, Taiwan 1965 Surveillance reports incidence. No time delays. Center for Disease Control
Cook Islands 1963 No data on imported malaria cases Ministry of Health
Fiji 1963 No data on imported malaria cases Ministry of Health
Japan x Surveillance reports incidence. No time delays. National Institute of Infectious
Diseases
Kiribati x No data on imported malaria cases Ministry of Health
Marshall
Islands
1963 No data on imported malaria cases Economic Policy, Planning and
Statistic Office
Micronesia
(Federated
States of )
1963 No data on imported malaria cases Department of Health and
social affairs
Mongolia 1963 No data on imported malaria cases National Center for Infectious
Diseases
Nauru 1963 Surveillance reports incidence. No time delays. International Health and
Medical Services (Australia)
New Zealand 1963 Surveillance reports incidence. No time delays. New Zealand Public Health
Observatory
Niue 1963 No data on imported malaria cases Statistics Niue
Palau 1963 No data on imported malaria cases Ministry of Health
Samoa 1963 No data on imported malaria cases Ministry of Health
Singapore 1982 Surveillance reports incidence. No time delays. Ministry of Health
8Tonga 1963 No data on imported malaria cases Ministry of Health
Tuvalu x No data on imported malaria cases Tuvalu Central statistics division
9A.2. Quality Assessment
Methods for Quality Assessment
Two reviewers independently examined the components of each included study for risk of bias. The
“JBI critical appraisal checklist for case series” was used since it was anticipated that the majority of
the included studies would be case series. 2 Furthermore, since the focus of the review is time to
diagnosis or treatment of malaria, the same checklist was used for cohort studies that report on the
variables of interest in the baseline characteristics of the sample. Although there are cohort specific
“risk of bias” assessment tools (e.g. Newcastle-Ottawa Scale /Downs and Black instrument), the use
of the case series checklist is justified since the baseline characteristics of these cohort studies is
descriptive.3,4 Any longitudinal and intervention related effects were not considered and the data
extracted from the studies comprised of only cases and was treated like a case series.
The checklist comprises of 10 items addressing the possibility of bias in the design, conduct and
analysis of case series studies. For each item, the reviewers assigned a “yes”, “no” or “unclear” on
whether the item in question had been addressed in the study. A guidance tool with criteria on what
comprises a “yes” or “no” answer was given to each of the reviewers. Discrepancies between the
reviewers (HB and JC) were resolved by consensus, and if necessary, a third party (GR) was
consulted.
Each of the included studies was given a score out of 10, with 1 point awarded for each “yes”
answer. This results in a scale; with a score of 10/10 having the lowest risk of bias and 0/10 having
the highest risk of bias.
Results of quality assessment
Most of the included studies had a clear inclusion criteria and the cases consisted of a lab confirmed
diagnosis of malaria, either by microscopy or antigen based testing, ensuring that the diagnosis of
malaria was reliable and objective (Questions 1, 2 and 3). In one third of the included studies the
selection of cases was not consecutive (26/69) and not all eligible cases were included (27/69), and
thus, would make these studies prone to selection bias (Questions 4 and 5). Most of the included
studies (67/69) provided clear information on the demographic and relevant clinical information of
the cases and therefore the risk of reporting bias within the included studies is low (Question 6 and
7). In 26/69 studies follow-up data of the cases were not available, however, since this review mainly
focuses on data prior to diagnosis and treatment, subsequent information regarding morbidity and
mortality does not have an effect on this review (Question 8). Information regarding the site where
the malaria cases presented was not available in 22/69 studies (Question 9) and therefore
information on PD, MDT and MTT within these studies might not be accurate since visits to a
healthcare provider prior to attending the reporting site might not have been considered, the
implications of this on the review are described in the discussion section. Finally, 10/69 studies
reported a median or mean delay with no measure of spread (IQR/SD) making it difficult to infer the
dispersion of reported delays within these studies (Question 10).
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Yeruva 2016 Yes Yes Yes Unclear Unclear Yes Yes Yes Yes No 7
Calvo-Cano 2016 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Teo 2015 Yes Yes Yes No No No Unclear Yes No Yes 5
Jaureguiberry 2015 Yes Yes Yes Unclear Unclear Yes Yes Yes Unclear yes 7
McCarthy 2015 Yes Yes Yes Yes Yes Yes Yes Yes No Yes 9
Broderick 2015 Yes Yes Yes Yes Yes Yes Yes No No Yes 8
Thompson 2015 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Chung 2014 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Grynberg 2015 Yes Unclear Unclear No No Yes Yes Yes Yes Yes 6
Dakic 2014 Yes Yes Yes Yes Yes Yes Yes No No Yes 8
Evans 2014 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Odolini 2014 Yes Unclear Unclear No No Yes Yes No No Yes 4
Stepien 2003 - 2015 Yes Yes Yes Yes Yes Yes Yes Yes No Yes 9
Rojo-Marcos 2014 Yes Yes Yes Yes Yes Yes Yes Yes No Yes 9
Nakayama 2014 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Cordel 2013 Yes Yes Yes No No Yes Yes Yes Yes Yes 8
Demaison 2013 Yes Yes Yes No No Yes Yes Yes Yes No 7
Maltezou 2013 Yes Yes Yes No No Yes Yes Yes Yes Yes 8
Marks 2013 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Roberts 2013 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Camburn 2012 Yes Yes Yes Yes Yes Yes Yes Unclear Yes Yes 9
Rossi 2012 Yes Yes Yes Yes Yes Yes Yes Yes Yes No 9
Santos 2012 Yes Yes Yes No No Yes Yes Yes Yes Yes 8
Checkley 2012 Yes Yes Yes Yes Yes Yes Yes No No Yes 8
Ramirez-
Olivencia 2012 Yes Yes Yes No No Yes Yes Yes Yes Yes 8
Antinori 2011 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
11
Phares 2011 Yes Yes Yes No No Yes Yes No No Yes 6
Minodier 2011 Yes Yes Yes No No Yes Yes Yes Yes Yes 8
Seringe 2011 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9
Rey 2010 Yes Yes Yes Yes No No Yes No Yes No 6
Bruneel 2010 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Arnaez 2010 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Ladhani 2010 Yes Yes Yes No No Yes Yes Yes No Yes 7
Pistone 2010 Yes Yes Yes Yes Yes Yes Yes No Yes No 8
Gonzalez 2009 Yes Yes Yes No No Yes Yes Yes Yes Yes 8
Dubos 2010 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9
Goldfarb 2009 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Leahy 2009 Yes Yes Yes Yes Yes Yes Yes Yes Yes No 9
Khan 2009 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Thierfelder 2009 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Millet 2008 Yes Yes Yes Yes Yes Yes Yes No No Yes 8
Blonde 2008 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Briand 2007 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Jennings 2006 Yes Yes Yes No No Yes Yes Yes Yes Yes 8
Christen 2006 Yes Yes Yes No No Yes Yes Unclear No Yes 6
Uzzan 2006 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Bottieu 2006 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Vatan 2006 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9
Chalumeau 2006 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9
Parola 2005 Yes Yes Yes Yes Yes Yes Yes No Yes No 8
Badiaga 2005 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Askling 2005 Yes Yes Yes No No Yes Yes No No Yes 6
Miura 2005 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Kitchener 2005 Yes Unclear Unclear No No Yes Yes Yes No No 4
Ben-Ami 2005 Yes Yes Yes No No Yes Yes Yes Unclear Yes 7
Charles 2005 Yes Yes Yes Yes Yes Yes Yes Yes No Yes 9
Fernandez-
Lopez 2015 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9
Kuna 2015 Yes Yes Yes No No Yes Yes Yes Yes Yes 8
Subelj 2012 Yes Yes Yes No No Yes Yes No No Yes 6
Higa 2013 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9
Soraa 2006 Yes Yes Yes No No Unclear Unclear Unclear Yes Yes 5
CNRP 2006 - 2010 Yes Yes Yes Yes Yes Yes Yes No No Yes 8
Alaya-Bouafif 2011 Yes Yes Yes Yes Yes Yes Yes No No Yes 8
D'Ortenzio 2008 Yes Yes Yes Yes Yes Yes Yes No No No 7
Bouchaud 2012 Yes Yes Yes No No Yes Yes Yes Yes No 7
Lanneaux 2016 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10
Hickey 2011 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9
Rabe 2005 Yes Yes Yes No No Yes Yes No Yes Yes 7
CDC 2003 - 2014 Yes Yes Yes Yes Yes Yes Yes No No Yes 8
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A.3. Number of studies contributing data for this review from each country
Table 2. A table listing the number of studies included in the review from each country
Country Number of studies
France 17
Spain 8
UK 6
USA 4
Australia 3
Canada 3
Japan 3
Multicentre 3
Switzerland 3
Israel 2
Poland 2
Tunisia 1
Belgium 1
Germany 1
Greece 1
Ireland 1
Italy 1
Le Reunion 1
Morocco 1
New Zealand 1
Portugal 1
Qatar 1
Serbia 1
Singapore 1
Slovenia 1
Sweden 1
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A.4. Overall summary of results for all study outcomes
Table 3 This table summarises the range of reported median and mean duration for the Time to Onset of Symptoms (TOS), diagnostic delay (DD), patient delay (PD), medical diagnostic
delay (MDD), treatment delay (TD) and medical treatment delay (MTD) from all studies included in the review.
Number of
studies
reporting
median
Range of reported
median duration
(days)
Number of
studies
reporting
mean
Range of reported
mean duration
(days)
Number of studies reporting
median and IQR and included
in the boxplot graphs
TOS P. falciparum 14 3 to 14 9 5.2 to 15.1 7
P. falciparum (severe) 5 5 to 7 1 7.9 3
P. falciparum (children) 4 2 to 7 1 11.7 3
P. vivax 14 28 to 240 9 61 to 282 7
P. vivax (children) 0 - 0 - 0
P. ovale 10 9.5 to 87 7 89.3 to 171.4 8
P. malariae 9 19 to 31 7 40.6 to 142.9 8
mixed 0 - 0 - 0
mixed (children) 2 32 to 52 0 - 0
DD P. falciparum 15 2 to 8 9 4 to 12.5 7
P. falciparum (severe) 4 5 to 7 3 3.1 to 6.2 3
P. falciparum (children) 4 2 to 4 2 4.7 to 5 1
P. vivax 6 3 to 5 3 6.5 to 18.3 3
P. vivax (children) 0 - 1 3 0
P. ovale 6 3.5 to 8 3 6.4 to 13 5
P. malariae 3 7 to 9 3 14.3 to 19.8 3
mixed 5 3 to 18 3 6.6 to 24 3
mixed (children) 0 - 0 - 0
PD P. falciparum 13 2 to 4 10 2.4 to 15.3 8
P. falciparum (severe) 8 3 to 7 2 4.2 to 5.6 5
P. falciparum (children) 8 1 to 5 2 3.1 to 5.7 4
P. vivax 5 3 to 8.5 4 3.6 to 16.7 4
P. vivax (children) 2 5 to 6.5 1 10 2
P. ovale 5 3 to 5 3 6.7 to 9.3 4
P. malariae 4 4 to 9 3 8.1 to 15.6 4
mixed 4 3 to 5 1 4.7 4
mixed (children) 1 2 0 - 0
MDD P. falciparum 0 - 1 0.7 -
P. falciparum (severe) 1 0 1 1.3 -
P. falciparum (children) 2 0 1 1.5 -
P. vivax 0 - 1 4.6 -
P. vivax (children) 0 - 0 - -
P. ovale 0 - 0 - -
P. malariae 0 - 0 - -
mixed 2 4 to 7.5 2 5.8 to 8.8 -
mixed (children) 0 - 0 - -
TD P. falciparum 0 - 1 4 -
P. falciparum (severe) 2 1.5 to 4 0 - -
P. falciparum (children) 0 - 0 - -
P. vivax 0 - 0 - -
P. vivax (children) 0 - 0 - -
P. ovale 0 - 0 - -
P. malariae 0 - 0 - -
mixed 0 - 0 - -
mixed (children) 0 - 0 - -
MTD P. falciparum 1 <1 1 0 -
P. falciparum (severe) 1 0.1 1 1.2 -
P. falciparum (children) 1 0.2 0 - -
P. vivax 0 - 1 0.3 -
P. vivax (children) 0 - 0 - -
P. ovale 0 - 0 - -
P. malariae 0 - 0 - -
mixed 0 - 0 - -
mixed (children) 1 2 0 - -
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A.5. Characteristics of the studies included in the systematic review
The characteristics and reported outcomes of the studies included in the review are summarised
below. Key: (*) = mean, (SD) = Standard Deviation, (IQR) = Interquartile range. Ranges are reported
in brackets.
Time to the Onset of Symptoms (TOS)
P. falciparum
Study
author (ref) Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum TOS (days)
Yeruva 5 2016 Retrospective chartreview USA
1998-
2012
Patients with a
positive blood smear
for malaria
37 84 8*
Dakic 6 2014 Retrospective chartreview Serbia
2010-
2014
CCS parasitology lab
cases malaria
(falciparum)
32 100 7·8* +/- 6·9 (0-30)
Camburn 7 2012
Prospective
Observational
Study
New
Zealand
2008-
2009
Laboratory confirmed
cases falciparum
malaria
18 100 3 (0-26)
Antinori 8 2011 Retrospective chartreview Italy
1997-
2007 Smear +ve falciparum 228 100 6
Phares 9 2011 Retrospective chartreview USA
2007-
2008
P. falciparum in
refugees who received
treatment for malaria
39 100 14 (3-46)
Seringe 10 2011 Retrospective chartreview France
1996-
2003
All patients with P.
falciparum who were
reported to CNRP
21,888 100 6 (IQR 1-12)
Khan 11 2009 Retrospective chartreview Qatar 2005
Lab confirmed
P.falciparum 34 100 14 (1-39)
Briand 12 2007 Retrospective chartreview France
1993-
2000
Lab confirmed P.
falciparum 400 100 4 (IQR 1-10)
Ben-Ami 13 2005 Retrospectivequestionnaire Israel
1999-
2001
Laboratory confirmed
P. falciparum without
chemoprophylaxis
22 100 14 (7-30)
Higa 14 2013 Retrospectivestudy Japan
1998-
2012
Laboratory confirmed
cases of P. falciparum 14 100
5·2 days
“average” (0-15)
CNRP 15 2010 NationalSurveillance data France 2010
Notified cases of
P.falciparum 1725 100
9* (SD 25·2) 5
(IQR 2-10)
CNRP 15 2009 NationalSurveillance data France 2009
Notified cases of
P.falciparum 1310 100
12·8* (SD 61·3)
6 (IQR 2-11)
CNRP 15 2008 NationalSurveillance data France 2008
Notified cases of
P.falciparum 1609 100
10·5* (SD 1·6) 4
(IQR 1-10)
CNRP 15 2007 NationalSurveillance data France 2007
Notified cases of
P.falciparum 1481 100
15·1* (SD 120·8)
5 (IQR 1-10)
CNRP 15 2006 NationalSurveillance data France 2006
Notified cases of
P.falciparum 1973 100
7·0* (SD 35·1) 4
(IQR 0-10)
D'Ortenzio 16 2008 NationalSurveillance data
Le
Reunion
2003-
2007
All reported cases of
malaria in Reunion 617 84·3 7
CDC17 2017 NationalSurveillance data USA
2003-
2014
P. falciparum cases
reported to the CDC 5637 100
9·6* (SD35·1) 5
(IQR 1-10)
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P. falciparum (Severe)
Study
author Year Study design Country
Study
period
description of study
participants
Sample
size
%
P.falciparum TOS (days)
McCarthy 18 2015 Retrospective chartreview Canada
2001-
2013
Patients with severe
malaria 248 94 7
Checkley 19 2012 Retrospective chartreview UK
1987-
2006 Fatal cases of malaria 135 100 5 (IQR 0-10)
Christen 20 2006 Retrospective chartreview Switzerland
1988-
2002 Fatal cases of malaria 33 100 7 (IQR 3-10)
Badiaga 21 2005 Retrospective chartreview France
1996-
2002
Patients >15 years
admitted with severe
malaria
(P.falciparum)
42 100 5 (0-21)
CDC17 2017 NationalSurveillance data USA
2003-
2014
Severe P. falciparum
cases reported to the
CDC
1123 100 7·9* (SD 24·9) 5(IQR 1-10)
P. falciparum (Children)
Study
author Year Study design Country
Study
period
description of study
participants
Sample
size
%
P.falciparum TOS (days)
Minodier 22 2011 Prospectiveobservational study France
2004-
2009
Children aged 3
months to 16 years
with uncomplicated
malaria
95 100 2 (IQR 8·25)
Dubos 23 2010 Retrospective chartreview France
2000-
2006
Children aged 18 and
under 120 83 7 (IQR 1-16)
Blonde 24 2008 Retrospective chartreview France
2004-
2005
Lab confirmed
P.falciparum in
Children (<15 years)
treated with
atovaquone-proguanil
48 100 4 (IQR 1-9)
CDC17 2017 NationalSurveillance data USA
2003-
2014
P. falciparum cases
reported to the CDC
(aged <18years)
1437 100 11·7* (SD 52·7)6 (IQR 1-11)
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P. vivax
Study author Year Study design Country Studyperiod
description of study
participants
Sample
size
%
P.vivax TOS (days)
Broderick 25 2015 observational study UK 1987-2013 Patients with P. vivax 12,769 100 68 (IQR 9-212)
Dakic 6 2014 Retrospective chartreview Serbia
2010-
2015
CCS parasitology lab
cases malaria (vivax) 4 100
61* +/- 99·7 ( 0-
210)
Odolini 26 2014 Retrospective chartreview Multicentre
2005-
2012
Eurotravnet database -
P. vivax imported from
Pakistan
45 100 282* (1-41,123)
Demaison 27 2013 retrospective chartreview France
2000-
2009 Lab confirmed P. vivax 94 100 49
Camburn 7 2012 ProspectiveObservational Study
New
Zealand
2008-
10
Laboratory confirmed
cases of vivax malaria 16 100 43 (10-274)
Antinori 8 2011 retrospective chartreview Italy
1997-
2007
Smear +ve non-
falciparum 58 73
Khan 11 2009 retrospective chartreview Qatar 2005 Lab confirmed P.vivax 39 100 28 (2-218)
Bottieu 28 2006 retrospective chartreview Belgium
2000-
2005 Lab confirmed P.vivax 48 100 66 (IQR 25-175)
Kitchener 29 2005 retrospective chartreview Australia
1999-
2001
Lab confirmed P. vivax
in Army personnel
returning from
deployment
241 100 89
Ben-Ami 13 2005 Retrospectivequestionnaire Israel
1991-
2001
Laboratory confirmed
P. vivax with
prophylaxis
3 100 240 (150-240)
Higa 14 2013 Retrospective study Japan 1998-2012
Laboratory confirmed
cases of P. vivax 7 100
85·6 "average" (2-
295)
CNRP 15 2010 NationalSurveillance data France 2010
Notified cases of
P.vivax 106 100
70·6* (SD 84) 38
(IQR 7-88)
CNRP 15 2009 NationalSurveillance data France 2009
Notified cases of
P.vivax 132 100
66·7* (SD 133·4)
38·5 (IQR 12·5-
70·5)
CNRP 15 2008 NationalSurveillance data France 2008
Notified cases of
P.vivax 85 100
89·1* (SD 12·0) 47
(IQR 13-121)
CNRP 15 2007 NationalSurveillance data France 2007
Notified cases of
P.vivax 92 100
123·2* (SD 251·1)
58 (IQR 28-136)
CNRP 15 2006 NationalSurveillance data France 2006
Notified cases of
P.vivax 119 100
111·6* (SD 258·5)
39 (IQR 6-129)
CDC17 2017 NationalSurveillance data USA
2003-
2014
P.vivax cases reported
to the CDC 1607 100
73·3* (SD 109·8)
25 (IQR 6-108)
17
P. ovale
Study author Year Study design Country Studyperiod
description of study
participants
Sample
size
% P.
ovale TOS (days)
Dakic 6 2014 Retrospective chartreview Serbia
2010-
2016
CCS parasitology lab
cases malaria (ovale) 6 100
165* +/-113·1 (72-
365)
Rojo-Marcos
(a) 30 2014
retrospective chart
review Spain
2005-
2011
Lab confirmed P. ovale
curtisi 21 100
94·5 (IQR 12·5-
297·2)
Rojo-Marcos
(b) 30 2014
retrospective chart
review Spain
2005-
2011
Lab confirmed P. ovale
wallikeri 14 100 9·5 (IQR 2·7-58·2)
Demaison 27 2013 retrospective chartreview France
2000-
2009 Lab confirmed P.ovale 77 100 71
Bottieu 28 2006 retrospective chartreview Belgium
2000-
2005 Lab confirmed P.ovale 34 100 70 (IQR 44-124)
CNRP 15 2010 NationalSurveillance data France 2010
Notified cases of
P.ovale 86 100
122·8* (SD 262·3)
50 (IQR 11-132)
CNRP 15 2009 NationalSurveillance data France 2009
Notified cases of
P.ovale 79 100
160* (SD 270·1)
87 (IQR 17-178)
CNRP 15 2008 NationalSurveillance data France 2008
Notified cases of
P.ovale 75 100
150·8* (SD 34·3)
58 (IQR 14-164)
CNRP 15 2007 NationalSurveillance data France 2007
Notified cases of
P.ovale 92 100
126·5* (SD 157·8)
73 (IQR 28-165)
CNRP 15 2006 NationalSurveillance data France 2006
Notified cases of
P.ovale 102 100
171·4* (SD 247·0)
86·5 (IQR 20-215)
CDC17 2017 NationalSurveillance data USA
2003-
2014
P. ovale cases reported
to the CDC 253 100
89·3* (SD 124·2)
45 (IQR 9-132)
P. malariae
Study author Year Study design Country Studyperiod
description of study
participants
Sample
size
% P.
malariae TOS (days)
Dakic 6 2014 Retrospective chartreview Serbia
2010-
2017
CCS parasitology lab
cases malaria
(malariae)
3 100 42·7* +/- 67 (2-120)
Bottieu 28 2006 Retrospective chartreview Belgium
2000-
2005
Lab confirmed
P.malariae 16 100 31 (IQR 10-105)
CNRP 15 2010 NationalSurveillance data France 2010
Notified cases of
P.malariae 37 100
142·9* (SD 668·5)
29 (IQR 9-46)
CNRP 15 2009 NationalSurveillance data France 2009
Notified cases of
P.malariae 35 100
47·4* (SD 54·8)
27 (IQR 13-62)
CNRP 15 2008 NationalSurveillance data France 2008
Notified cases of
P.malariae 42 100
57* (SD 18·8) 24
(IQR 15-55)
CNRP 15 2007 NationalSurveillance data France 2007
Notified cases of
P.malariae 32 100
40·6* (SD 41·7)
31 (IQR 14-58)
CNRP 15 2006 NationalSurveillance data France 2006
Notified cases of
P.malariae 38 100
48·4* (SD 72·0)
29 (IQR 10-54)
Teo (a) 31 2015 Retrospectivereview Sweden
1997-
2013
Cases P.malariae
Sweden 20 100
19 (IQR 13-47)
(0-70)
Teo (b) 31 2015 Retrospectivereview UK
1991-
2010 Cases P.malariae UK 248 100
24 (IQR 9-50)(-5 -
1123)
CDC17 2017 NationalSurveillance data USA
2003-
2014
P. malariae cases
reported to the CDC 258 100
49·7* (SD 111·6)
17 (IQR 4-57)
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Mixed malaria in children
Study author Year Study design Country Studyperiod
description of study
participants
Sample
size
% P.
falciparum TOS (days)
Thompson 32 2015 retrospective chartreview Australia
2000-
2010
Children aged 16 and
under 40 68 32 (4-434)
Maltezou 33 2013 retrospective chartreview Greece
1972-
2012
Children aged 15 and
under 22 32
50 (4 days - 16
months)
19
Diagnostic delay
P. falciparum
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Diagnostic
delay (days)
Cordel 34 2013
prospective
observational
study
France 2002-2007
Lab confirmed
uncomplicated P.falciparum 553 100 5 (1-64)
Ramirez-
Olivencia 35 2012
retrospective
chart review Spain
2002-
2007 Symptomatic malaria 277 86.4 8·16* (SD 16)
Bouchaud36 2012
prospective
observational
study
Multi
centre
2003 -
2009 Uncomplicated P. falciparum 504 100 3
Antinori 8 2011 retrospectivechart review Italy
1997-
2007 Smear +ve P. falciparum 228 100 3 (0-10)
Seringe 10 2011 retrospectivechart review France
1996-
2003
All patients with P.
falciparum who were
reported to CNRP
21,888 100 3 (IQR 1-6)
Rey 37 2010 retrospectivechart review Spain
2005-
2008
Malaria cases notified to
preventative medicine
department
57 94·7 4·5
Pistone 38 2010 retrospectivechart review France
2000-
2007
Lab confirmed malaria in
those aged > 15 years 488 82 3
Khan 11 2009 retrospectivechart review Qatar 2005 Lab confirmed P.falciparum 34 100 3(2-6)
Thierfelder
39 2009
retrospective
chart review Switzerland
1994-
2004
Those diagnosed with
malaria aged >16 years 109 88 4* (0·5-31)
Millet 40 2008 retrospectivechart review Spain
1989-
2005
Lab confirmed malaria
notified to Barcelona Public
Health Agency
997 71 8 (IQR 5-20)
Briand 12 2007 retrospectivechart review France
1993-
2000 Lab confirmed P. falciparum 400 100 4 (IQR 2-7)
Jennings 41 2006
prospective
observational
study
UK 2000-2002
Patients admitted to HTD
with P.falciparum -
uncomplicated
74 100 4·29* (1-60)
Uzzan (a) 42 2006 PreliminaryStudy France
2003-
2004
Cases P. falciparum with
raised procalcitonin 6 100 12·5* +/-7·7
Uzzan (b) 42 2006 PreliminaryStudy France
2003-
2004
Cases P. falciparum malaria
without raised procalcitonin 11 100 5·3* +/- 3·1
Fernandez-
Lopez 43 2015
retrospective
chart review Spain
2004-
2014 Lab confirmed malaria 185 90·3 4 (IQR 2·5-7)
Soraa 44 2006 retrospectivechart review Morocco
2001-
2004 Lab confirmed malaria 68 85·3 18* (1-90)
CNRP 15 2010
National
Surveillance
data
France 2010 Notified cases of P.falciparum 1,866 100
5·7* (SD 11·5)
3 (IQR 2-6)
CNRP 15 2009
National
Surveillance
data
France 2009 Notified cases of P.falciparum 1,644 100
8·8* (SD 92·6)
3 (IQR 2-6)
D'Ortenzio
16 2008
National
Surveillance
data
Le Reunion 2003-2007
All reported cases of malaria
in Reunion 617 84·3 3
Rabe 45 2005 retrospectivechart review Germany
1992-
2002
Lab confirmed P. falciparum
(Uncomplicated) 73 100 2 (0-24)
Stepien46 2017
National
Surveillance
data
Poland 2003-2015 Lab confirmed P. falciparum 181 100
5·26* (SD 7·2)
3 (IQR 2-6)
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P. falciparum (Severe)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Diagnostic
delay (days)
Checkley
19 2012
retrospective
chart review UK
1987-
2006 Fatal cases of malaria 146 100 5 (IQR 3-7)
Bruneel
(a) 47 2010
retrospective
chart review France
2000-
2006
Adults admitted to ICU with
severe malaria + survived 358 100 5·4* (SD 5·1)
Bruneel
(b) 47 2010
retrospective
chart review France
2000-
2006
Adults admitted to ICU with
severe malaria + died 42 100 6·2* (SD 4·6)
Gonzalez
48 2009
retrospective
chart review Spain
1991-
2007
Adults admitted to ICU with
severe malaria 20 100
7 (IQR 3·75-
9·25)
Jennings
41 2006
prospective
observational
study
UK 2000-2002
Patients admitted to HTD
with P.falciparum - severe 25 100 3·08* (1-10)
Christen 20 2006 retrospectivechart review Switzerland
1988-
2002 Fatal cases of malaria 33 100 5 (IQR 3·75-6)
Rabe 45 2005 retrospectivechart review Germany
1992-
2003
Lab confirmed P. falciparum
(Severe) 44 100 5 (0-30)
P. falciparum (Children)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Diagnostic
delay (days)
Minodier
22 2011
prospective
observational
study
France 2004-2009
Children aged 3 months to 16
years with uncomplicated
malaria
95 100 3 (IQR 4·25)
Dubos 23 2010 retrospectivechart review France
2000-
2006 Children aged 18 and under 120 83 2
Blonde 24 2008 retrospectivechart review France
2004-
2005
Lab confirmed P.falciparum in
Children (<15 years) treated
with atovaquone-proguanil
48 100 3 (IQR 2-5)
Chalumeau
49 2006
prospective
observational
study
France 2002 Lab confirmed P. falciparum inchildren <18 years 29 100 4 (0-19) 4·7*
Hickey50 2011 retrospectivechart review USA
1996-
2006
Lab confirmed P. falciparum in
children <18 years 72 100 5* (SD 5·4 )
P. vivax
Study
author Year Study design Country
Study
period Description of study participants
Sample
size
% (n)
P.vivax
Diagnostic
delay (days)
Demaison
27 2013
retrospective
chart review France
2000-
2009 Lab confirmed P. vivax 94 100 4·5
Antinori 8 2011 retrospectivechart review Italy
1997-
2007 Smear +ve non-falciparum 58 76·2 5 (0-47)
Khan 11 2009 retrospectivechart review Qatar 2005 Lab confirmed P.vivax 39 100 3(1-6)
CNRP 15 2010
National
Surveillance
data
France 2010 Notified cases of P.vivax 119 100 6·5* (SD 16·7)3 (IQR 2-8)
CNRP 15 2009
National
Surveillance
data
France 2009 Notified cases of P.vivax 157 100 18·3* (SD 61·1)3 (IQR 0-8)
Stepien46 2017
National
Surveillance
data
Poland 2003-2015 Lab confirmed P. vivax 51 100
8·7* (SD 10·0)
5 (3-11)
21
P. vivax (Children)
Study
author Year Study design Country
Study
period Description of study participants
Sample
size
% (n)
P.vivax
Diagnostic
delay (days)
Hickey50 2011 retrospectivechart review USA
1996-
2006
Lab confirmed P. vivax in children
<18 years 3 100 3* (SD 2·3)
P. ovale
Study
author Year Study design Country
Study
period Description of study participants
Sample
size
% (n)
P.ovale
Diagnostic
delay (days)
Rojo-
Marcos (a)
30
2014 retrospectivechart review Spain
2005-
2011 Lab confirmed P. ovale curtisi 21 100
8 (IQR 2·7-
16·5)
Rojo-
Marcos (b)
30
2014 retrospectivechart review Spain
2005-
2011 Lab confirmed P. ovale wallikeri 14 100
3·5 (IQR 2·0-
7·7)
Demaison
27 2013
retrospective
chart review France
2000-
2009 Lab confirmed P.ovale 77 100 4
CNRP 15 2010
National
Surveillance
data
France 2010 Notified cases of P.ovale 98 100 7·8* (SD 18·6)5 (IQR 2-7)
CNRP 15 2009
National
Surveillance
data
France 2009 Notified cases of P.ovale 102 100 13* (SD 50·7) 5(IQR 2-8)
Stepien46 2017
National
Surveillance
data
Poland
2003-
2015
Lab confirmed P.ovale 7 100
6·4* (SD 4·9) 4
(IQR 3-13)
P. malariae
Study
author Year
Study
design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.malariae
Diagnostic
delay (days)
CNRP 15 2010
National
Surveillance
data
France 2010 Notified cases of P.malariae 46 100 15* (SD 21·1) 8(IQR 3-14)
CNRP 15 2009
National
Surveillance
data
France 2009 Notified cases of P.malariae 47 100 14·3* (SD 18·2)9 (IQR 4-17)
Stepien46 2017
National
Surveillance
data
Poland
2003-
2015
Lab confirmed P. malariae 5 100
19·8* (SD 29·4)
7 (IQR 5-12)
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Mixed species / Unknown species
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Diagnostic
delay (days)
Charles 51 2005 Questionnaire Australia 1990-2001
Cases diagnosed with malaria
and notified to Western
Australian Notifiable ID register
283 28 3 (0-336)
Subelj 52 2012 retrospectivechart review Slovenia
2001-
2011 Lab confirmed malaria 73 42·5 18 (1-136) 24*
Kuna 53 2015 retrospectivechart review Poland
2002-
2014
Patients admitted to hospital
with lab confirmed malaria 82 63·4 6·6* (1-28)
Alaya-
Bouafif (a)
54
2011
National
Surveillance
data
Tunisia 2002-2007
Notified cases of malaria
amongst Tunisian Patients 55 N/A 14 (IQR 15)
Alaya-
Bouafif
(b) 54
2011
National
Surveillance
data
Tunisia 2002-2007
Notified cases of malaria
amongst Patients of other
nationalities (non-Tunisian)
52 N/A 12·5 (IQR 20)
Stepien46 2017
National
Surveillance
data
Poland
2003-
2015
Malaria cases with mixed
invasions
10 N/A
9·5* (SD 9·2)
7·5 (IQR 5-10)
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Patient Delay
P. falciparum
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Patient
delay
(days)
Farnert 55 2015 retrospective chartreview Sweden
1995-
2013
Compares VFR to
non VFR's - data
combined
501 100 2·5
Roberts 56 2013 retrospective chartreview UK
2001-
2011
Adults >18 years
with lab confirmed
falciparum
773 100 4 (IQR 2-7)
Rossi 57 2012 retrospective chartreview Switzerland
1999-
2007
Adults >16 years
with lab confirmed
falciparum
154 100 3·9*
Vatan 58 2006 retrospective chartreview France
2001-
2002
Lab confirmed
P.falciparum in
adults
107 100 3 (0-98)9·17*
Parola 59 2005 prospectiveobservational study France
2002-
2003
Lab confirmed P.
falciparum in adults
>15 years
212 100 4
Askling 60 2005 Questionnaire Sweden 1994-2001
Questionnaires sent
to patients
diagnosed with
P.falciparum
237 100 2 (0-71)
Miura 61 2005 retrospective chartreview Japan
1992-
2001
Lab confirmed
P.falciparum 50 100
4·1*
(95%CI 2·5-
5·7) 2 (IQR
1-5)
Soraa 44 2006 retrospective chartreview Morocco
2001-
2004
Lab confirmed
malaria 68 85·3 2
Higa 14 2013 Retrospective study Japan 1998-2012
Laboratory
confirmed cases of P.
falciparum
14 100
2·4
"average"
(0-5)
CNRP 15 2010 NationalSurveillance data France 2010
Notified cases of
P.falciparum 1840 100
5·9* (SD
12·5) 3
(IQR 2-6)
CNRP 15 2009 NationalSurveillance data France 2009
Notified cases of
P.falciparum 1630 100
8·6* (SD
93·9) 3
(IQR 2-6)
CNRP 15 2008 NationalSurveillance data France 2008
Notified cases of
malaria 1885 86
5·6* (SD
0·3) 3 (IQR
2-6)
CNRP 15 2007 NationalSurveillance data France 2007
Notified cases of
malaria 1782 86
7·3* (SD
22·6) 3
(IQR 2-6)
CNRP 15 2006 NationalSurveillance data France 2006
Notified cases of
malaria 2359 82·6
15·3* (SD
60·7) 4
(IQR 2-9)
CDC17 2017 NationalSurveillance data USA
2003-
2014
P. falciparum cases
reported to the CDC 4183 100
5·5* (SD
15·3) 4
(IQR 2-6)
P. falciparum (Severe)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Patient
delay
(days)
Calvo-
Cano 62 2016
retrospective chart
review Spain
2013-
2015
Patients diagnosed
with severe malaria 16 100 5 (2·5-11·7)
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Santos (a)
63 2012
retrospective chart
review Portugal
1990-
2011
Adults admitted to
ICU with severe
malaria + survived
50 100 7 (IQR 4-9)
Santos (b)
63 2012
retrospective chart
review Portugal
1990-
2011
Adults admitted to
ICU with severe
malaria + died
9 100 6 (IQR 4-8)
Gonzalez
48 2009
retrospective chart
review Spain
1991-
2007
Adults admitted to
ICU with severe
malaria
20 100 4·5 (IQR 3-8·5)
Badiaga 21 2005 retrospective chartreview France
1996-
2002
Patients >15 years
admitted with severe
malaria (P.falciparum)
42 100 3 (0-10)
Marks 64 2013 retrospective chartreview UK
1994-
2010
Adults >18 years with
severe malaria
admitted to ICU
124 100 4 (IQR 3-6)
McCarthy
18 2015
retrospective chart
review Canada
2001-
2013
Patients with severe
malaria 248 94
3 (0-50)
4·2* (SD
5·3)
CDC17 2017 NationalSurveillance data USA
2003-
2014
Severe P. falciparum
cases reported to the
CDC
1075 100
5·6* (SD
9·5) 4 (IQR
2-6)
P. falciparum (Children)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Patient
delay
(days)
Evans 65 2014 retrospective chartreview Canada
1997-
2013
Lab confirmed P.
falciparum in
children <18 years
76 100 4 (IQR 2-7)
Arnaez 66 2010 retrospective chartreview Spain
1995-
2007
Children aged 14 and
under 60 72
4 (0·5-
1095)
Ladhani 67 2010 prospectiveobservational study UK
2006-
2007
Children aged 16 and
under 172 86 4 (IQR 2-6)
Dubos 23 2010 retrospective chartreview France
2000-
2006
Children aged 18 and
under 120 83 1
Leahy 68 2009 retrospective chartreview Ireland
1999-
2006
malaria cases
admitted to
children’s hospital
67 95 5
Chalumeau
49 2006
prospective
observational study France 2002
Lab confirmed P.
falciparum in
children <18 years
29 100 3 (0-11)3·1*
Lanneaux
69 2016
retrospective case
control study France
2006-
2012
Children aged <18
years admitted to ED
(controls)
110 100 2 (IQR 1-5)
CDC17 2017 NationalSurveillance data USA
2003-
2014
P. falciparum cases
reported to the CDC
(aged <18 years)
1089 100
5·7* (SD
10·2) 4
(IQR 2-6)
P. vivax
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.vivax
Patient
delay
(days)
Higa 14 2013 Retrospective study Japan 1998-2012
Laboratory confirmed
cases of P. vivax 7 100
3·6
"average"
(0-9)
CNRP 15 2010 National Surveillancedata France 2010
Notified cases of
P.vivax 117 100
8·6* (SD
29·9) 3 (IQR
2-7)
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CNRP 15 2009 National Surveillancedata France 2009
Notified cases of
P.vivax 157 100
16·7* (SD
62·3) 3 (IQR
1-9)
Bottieu 28 2006 retrospective chartreview Belgium
2000-
2005 Lab confirmed P.vivax 48 100 5 (IQR 3-6)
Parola 59 2005 prospectiveobservational study France
2002-
2003
Lab confirmed P. vivax
in adults >15 years 10 100 8·5
CDC17 2017 National Surveillancedata USA
2003-
2014
P.vivax cases reported
to the CDC 1161 100
7* (SD 12·7)
4 (IQR 2-8)
P. vivax (Children)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.vivax
Patient
delay
(days)
Evans 65 2014 retrospective chartreview Canada
1997-
2013
Lab confirmed P. vivax
in children <18 years 28 100
6·5 (IQR 3-
11·5)
CDC17 2017 National Surveillancedata USA
2003-
2014
P. vivax cases reported
to the CDC (aged <18
years)
184 100
10* (SD
20·3) 5 (IQR
2·5-10)
P. ovale
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.ovale
Patient
delay
(days)
CNRP 15 2010 National Surveillancedata France 2010
Notified cases of
P.ovale 97 100
7·7* (SD
18·7) 4 (IQR
2-7)
CNRP 15 2009 National Surveillancedata France 2009
Notified cases of
P.ovale 102 100
9·3* (SD
36·6) 4 (IQR
2-8)
Bottieu 28 2006 retrospective chartreview Belgium
2000-
2005 Lab confirmed P.ovale 34 100 5 (IQR 3-7)
Parola 59 2005 prospectiveobservational study France
2002-
2003
Lab confirmed P. ovale
in adults >15 years 6 100 3
CDC17 2017 National Surveillancedata USA
2003-
2014
P.ovale cases reported
to the CDC 177 100
6·7* (SD
8·6) 4 (IQR
2-7)
P. malariae
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.malariae
Patient
delay
(days)
CNRP 15 2010 National Surveillancedata France 2010
Notified cases of
P.malariae 45 100
15·6* (SD
21·2) 9 (IQR
3-15)
CNRP 15 2009 National Surveillancedata France 2009
Notified cases of
P.malariae 45 100
14·4* (SD
18·5) 9 (IQR
3-17)
Bottieu 28 2006 retrospective chartreview Belgium
2000-
2005
Lab confirmed
P.malariae 16 100
7 (IQR 4-
13)
CDC17 2017 National Surveillancedata USA
2003-
2014
P. malariae cases
reported to the CDC 172 100
8·1* (SD
15·3) 4 (IQR
2-9)
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Mixed species / Parasite species not reported
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Patient
delay
(days)
Alaya-
Bouafif
(a) 54
2011 NationalSurveillance data Tunisia
2002-
2007
Notified cases of
malaria amongst
Tunisian Patients
54 N/A 5 (IQR 6)
Alaya-
Bouafif
(b) 54
2011 NationalSurveillance data Tunisia
2002-
2007
Notified cases of
malaria amongst
Patients of other
nationalities (non-
Tunisian)
39 N/A 5 (IQR 3)
Chung 70 2014 retrospective chartreview Singapore
2000-
2010
Adults with smear
+ve malaria 214 34 (83) 4 (IQR 3-7)
Miura 61 2005 retrospective chartreview Japan
1992-
2001
Lab confirmed
malaria 101 49·5 (50)
4·7* (95%
CI 3·7-5·7)
3 (IQR 2-5)
Mixed species / Parasite species not reported (Children)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Patient
delay
(days)
Parola 59 2005 Prospectiveobservational study France
2002-
2003
Lab confirmed
malaria in children
<15 years
42 N/A 2 (0-42)
Medical Diagnostic Delay
P. falciparum
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Medical
diagnostic delay
(days)
Higa 14 2013 Retrospectivestudy Japan
1998-
2012
Laboratory confirmed
cases of P. falciparum 14 100
0·7 days "average"
(0-4)
P. falciparum (Severe)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Medical
diagnostic delay
(days)
McCarthy
18 2015
Retrospective
chart review Canada
2001-
2013
Patients with severe
malaria 248 94
0 (0-864) 30·2*
(SD 94·94) (hours)
P. falciparum (Children)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Medical
diagnostic delay
(days)
Dubos 23 2010 retrospectivechart review France
2000-
2006
Children aged 18 and
under 120 83 0 (IQR 0-1)
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Chalumeau
49 2006
prospective
observational
study
France 2002
Lab confirmed P.
falciparum in
children <18 years
29 100 0 (0-19) 1·5*
P. vivax
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.vivax
Medical diagnostic
delay (days)
Higa 14 2013 Retrospectivestudy Japan
1998-
2012
Laboratory confirmed
cases of P. vivax 7 100
4·6 "average" (0-18
range)
Mixed species
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Medical
diagnostic delay
Nakayama
(a) 71 2014
Retrospective
report Japan
1991-
2000
Laboratory
confirmed cases
malaria 1st decade
14 35·7
8·8* (95%CI 5·9-
11·7) 7·5 (IQR 5·8-
11·8)
Nakayama
(b) 71 2014
Retrospective
report Japan
2001-
2010
Laboratory
confirmed cases
malaria 2nd decade
13 69·2 5·8* (95%CI 3·3 -8·3) 4 (IQR 3-9)
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Treatment delay
P. falciparum
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
% (n)
P.falciparum
Treatment
delay
(days)
Grynberg 72 2015 retrospectivechart review Israel
2001-
2013
Adult Israeli travellers
with uncomplicated
P.falciparum
63 100 4* (SD6·4)
P. falciparum (Severe)
Study author Year Study design Country Studyperiod
Description of study
participants
Sample
size
% (n)
P.falciparum
Treatment
delay
(days)
Jaureguiberry
(a) 73 2015
retrospective
chart review France
2011-
2013
Patients who
received IV
artesunate and died
6 100 1·5 (1-5)
Jaureguiberry
(b) 73 2015
retrospective
chart review France
2011-
2013
Patients who
received IV
artesunate and
recovered
117 100 4 (2-5)
Medical treatment delay
P. falciparum
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Medical
treatment
delay
(days)
Askling 60 2005 Questionnaire Sweden 1994-2001
Questionnaires (58%
response rate) sent to
patients diagnosed with
P.falciparum
237 100 <1 (0-60)
Higa 14 2013 Retrospectivestudy Japan
1998-
2012
Laboratory confirmed
cases of P. falciparum 14 100
0 "average"
(0)
P. falciparum (Severe)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Medical
treatment
delay (days)
McCarthy
18 2015
retrospective
chart review Canada
2001-
2013
Patients with severe
malaria 248 94
2 (0-864)
29·9* (SD
91·6)
(hours)
P. falciparum (Children)
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Medical
treatment
delay
(days)
Goldfarb
74 2009
retrospective
chart review Canada
1999-
2006
Children treated for
malaria after to
implementation of
protocol
19 95
5·5 (IQR 3-
9·25)
(hours)
29
P. vivax
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.vivax
Medical
treatment
delay (days)
Higa 14 2013 Retrospectivestudy Japan
1998-
2012
Laboratory confirmed cases
of P. vivax 7 100
0·3
"average"
(0-1 range)
Mixed species in children
Study
author Year Study design Country
Study
period
Description of study
participants
Sample
size
%
P.falciparum
Medical
treatment
delay (days)
Maltezou
33 2013
retrospective
chart review Greece
1972-
2012
Children aged 15 and
under 22 32 2 (1-4)
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